Mitchell S. Cairo

New York Medical College — United States

Medicine · Health Sciences

83h-index27.4kcitations1.0kworks0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(280), Lymphoma Diagnosis and Treatment(269), Acute Lymphoblastic Leukemia research(227), Immune Cell Function and Interaction(174), CAR-T cell therapy research(156)

Publications1.0k total

A framework integrating multiscale in silico modeling and experimental data predicts CAR-NK cell cytotoxicity across target cell types
Proceedings of the National Academy of Sciences·2026Open Access
Comment on: Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group AALL1331 trial
Haematologica·2026Open Access
243 IL-1 Signaling Blockade Mitigates Inflammation and Improves Survival in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa
Journal of Investigative Dermatology·2025Open Access
Rasburicase vs. allopurinol: mortality in hematological malignancies post anti-hyperuricemic therapy - real-world study
Supportive Care in Cancer·2025Open Access
Identification of the MIF-CD74/CD44 signaling axis as a therapeutic target in pediatric Acute Myeloid Leukemia
Blood·2025
Enhancing CD33.CAR NK cell therapy for acute myeloid leukemia through TGFβ imprinting and NKTR-255
Blood·2025Open Access
649 Combination IL-1RAP-targeted chimeric antigen receptor natural killer cell therapy and adjuvant immunomodulation to treat acute myeloid leukemia
Regular and Young Investigator Award Abstracts·2025Open Access
310 Targeting osteosarcoma by ex-vivo expanded NK cells in combination with IL-15 agonist and anti-GD2 antibody
Regular and Young Investigator Award Abstracts·2025Open Access
642 Synergistic anti-leukemic effect of NKTR-255 and TGFβ-imprinted CD33.CAR natural killer cells
Regular and Young Investigator Award Abstracts·2025Open Access
650 Enhanced cytotoxicity of anti-ROR1 CAR NK cells against glioblastoma via combined treatment with oncolytic virus and NKTR-255
Regular and Young Investigator Award Abstracts·2025Open Access
Targeted immunotherapy in the treatment of childhood and adolescent mature B-cell lymphoma.
PubMed·2025
Advances in augmenting infiltration of active natural killer cells into pediatric and adult solid tumors
Molecular Therapy Oncology·2025· 2 citedOpen Access
CXCL10-induced chemotaxis of ex vivo-expanded natural killer cells combined with NKTR-255 enhances anti-tumor efficacy in osteosarcoma
Molecular Therapy Oncology·2025· 2 citedOpen Access
RASBURICASE VS. ALLOPURINOL: MORTALITY IN HEMATOLOGICAL MALIGNANCIES POST ANTI HYPERURICEMIC THERAPY – REAL-WORLD STUDY
Leukemia Research·2025
FAMILIAL DONOR HAPLOIDENTICAL EPSTEIN-BARR VIRUS (EBV)-SPECIFIC CYTOTOXIC T-LYMPHOCYTES (CTLs) FOR RESISTANT INFECTIONS IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS (CAYA) POST HEMATOPOIETIC STEM CELL TRANSPLANTATION (AlloHSCT), AND SOLID ORGAN TRANSPLANT (SOT)
Leukemia Research·2025Open Access
ENHANCING CD20.CAR NK CELL THERAPY IN RITUXIMAB-RESISTANT BURKITT LYMPHOMA USING IL-15-BASED IMMUNOMODULATORS WITH NKTR-255 OR ANTI-CD16-IL15-ANTI-CD19 TRIKE
Leukemia Research·2025Open Access
TARGETED IMMUNOTHERAPY IN CHILDREN, ADOLESCENTS, ANDYOUNG ADULTS (CAYA) WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA, A SINGLE CENTER EXPERIENCE
Leukemia Research·2025
A PHASE I TRIAL OF TARGETED IMMUNOTHERAPY WITH DARATUMUMAB FOLLOWING MYELOABLATIVE TOTAL BODY IRRADIATION (TBI)-BASED CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH HIGH-RISK T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA (T-ALL/T-LLy) (ALLO-T-DART): A PTCTC FACILITATED STUDY
Leukemia Research·2025
SAFETY AND TOLERABILITY OF MYELOABLATIVE CONDITIONING AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOLLOWED BY POLATUZUMAB VEDOTIN IN B-CELL NON-HODGKIN LYMPHOMA
Leukemia Research·2025
COMBINATIONAL NATAURAL KILLER (NK) CELL-BASED IMMUNOTHERAPY TO CIRCUMVENT RESISTANCE IN RITUXIMAB-RESISTANT BURKITT LYMPHOMA (BL)
Leukemia Research·2025
page 1 of 52Next →

Frequent Co-authors

Robert Peter Gale(12), Hillard M. Lazarus(11), Mark R. Litzow(8), Sherrie L. Perkins(8), Catherine Patte(7), Corey Cutler(6), Mei-Jie Zhang(6), Brian J. Bolwell(6), Christopher Bredeson(6), Daniel J. Weisdorf(6), Mary M. Horowitz(6), David I. Marks(6), Richard Sposto(6), Thomas G. Gross(6), Olle Ringdén(6), Gregory A. Hale(6), Harry C. Schouten(6), John E. Wagner(5), Edward A. Copelan(5), Marcos de Lima(5)